TruWealth Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

TruWealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,652 shares of the company’s stock after purchasing an additional 161 shares during the quarter. TruWealth Advisors LLC’s holdings in Johnson & Johnson were worth $817,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Bank of America lowered their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $174.29.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.5 %

Shares of Johnson & Johnson stock opened at $147.03 on Monday. The stock’s fifty day moving average is $148.51 and its 200-day moving average is $156.03. The firm has a market capitalization of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.